AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06560268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane; In our study, the effects of sevoflurane in different FGFs administered in children undergoing strabismus surgery on EA and anesthetic agent consumption will be investigated.
Description: Low-flow anaesthesia is generally adminstered as nitrogen wash-out, a period of higher flow rate in combination with a high vaporizer setting for initial saturation, and subsequent reduction of fresh gas flow and adjustment of the vaporizer to maintain the desired end-tidal anesthetic agent concentration (Etaa).In the initial wash-in phase, the vaporizer setting is adjusted to 6% for desflurane and 2.5-3% for sevoflurane, with FGF=4 L/min, until the Etaa concentration is 1-1.3 MAC. In another method, the vaporizer setting is adjusted to 12-18% for desflurane and 6-8% for sevoflurane, with FGA=1 L/min. Reducing the FGF during the wash-in period prevents unnecessary depth of anesthesia and reduces the consumption of inhalational anesthetics. In LFA using minimal FGF (250-500 mL/min), if the vaporizer is turned off 10-15 min before the end of the operation and the FGF is not changed, the inhaled anesthetic agent concentration gradually and slowly decreases to zero.
Study NCT05148494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fleet Enema
Description: standard pre-op application, see arm description
Study NCT05148494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pico-Salax
Description: standard pre-op application, see arm description
Study NCT05919329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET/CT Scan
Description: Undergo PSMA PET/CT
Study NCT04551469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music
Description: Music intervention for 30 minutes
Study NCT05362279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: One month after the pre-test, the post-test will be administered to the nurses who will be in the control group.~Nurses who will be in the experimental group will be given training after the pre-test. A post-test will be administered one month after the training.
Study NCT05919329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET/MRI scan
Description: Undergo PET/MRI
Study NCT05919329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05919329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06449911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: 300 lines and 10,200 dots will be performed to each half lower two-thirds of the face and submental area of every participant.
Study NCT05359003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week physical activity program
Description: Program aimed to achieve the equivalent of 8,000 steps per day (56,000 weekly steps). Includes weekly meetings with a trained health coach.
Study NCT04417907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel 1 week titration
Description: Healthy adults will take 2mg perampanel PO QD for one week followed 4mg perampanel PO QD for five weeks.
Study NCT04417907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel 2 week titration
Description: Healthy adults will take 2mg perampanel PO QD for two weeks followed 4mg perampanel PO QD for four weeks.
Study NCT04417907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel 4mg
Description: Healthy adults will take 4mg perampanel PO QD for six weeks
Study NCT04417907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthy adults will take 2mg placebo PO QD for six weeks
Study NCT05810961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod IV
Description: infusion of efgartigimod
Study NCT05810961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: infusion of placebo
Study NCT05777174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102
Description: 130 mg administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30-60 seconds.
Study NCT05777174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Description: On treatment day, participants will have the TGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon® Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements will be collected for 12-24 hours. For those with significant renal compromise, fluorescent measurements will continue until the sensor no longer detects MB-102 in the body.
Study NCT00879294 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Motion sickness wristband
Description: No drugs are involved.
Study NCT00879294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewing Gum
Description: Patients will be asked to chew gum for 20 minutes, four times daily.
Study NCT05211037 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Kidney function assessment
Description: kidney clearance measured by scintigraphy
Study NCT05507606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: osimertinib 80mg/d
Study NCT05430308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine scrub
Description: Surgical site selected for performing the thoracoscopy will be cleaned with 4%w/v chlorhexidine gluconate solution for 3 minutes
Study NCT05430308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-iodine
Description: The surgical site selected for performing the thoracoscopy will be just cleaned with normal saline followed by 10% w/v povidone-iodine solution
Study NCT05507606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Biosimilar IBI305
Description: Bevacizumab, 7.5mg/kg d1; was discontinued after 2 years
Study NCT05507606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC5, d1; was stopped after 4 cycles
Study NCT05507606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, 500mg/m2, d1;Q3W/cycle; was discontinued after 2 years
Study NCT05484830 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Individualized HDR-approach
Description: Heparin concentration necessary to achieve target ACT > 480 sec. calculated based on individual HDR-curve.~If HDR slope ˂80 s/IU/mL (reduced sensitivity to heparin), 1000 IU of AT concentrate (Antitrombin III Baxalta®, Takeda Pharma, Vallensbæk Strand, DK). Whole blood concentration of circulating heparin assessed by heparin assays. Additional heparin given as required. After weaning, protamine necessary to reverse circulating heparin calculated according to heparin-protamine titration measurement. After protamine, heparin reversal evaluated with low-range heparin-protamine titration cartridge and additional protamine given as required.
Study NCT05484830 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ACT-approach
Description: Initial Heparin 400 IU/kg (500 IU/kg if treated with heparin prior to surgery). ACT Assessment with Hemochron® Signature Elite (ITC, International Technidyne Corp., Edison, NJ, USA).~Additional heparin until ACT > 480 sec. If ACT \< 480 sec. after despite repeated heparin supplement with 1000 IU of AT III concentrate. Target ACT > 480 sec. during normothermic CPB, and target ACT > 700 seconds during hypothermia After weaning, protamine 10mg/mL (0.7 mg of protamine/ 100 IU total heparin administered). Heparin reversal is evaluated with an activated partial thromboplastin (APTT). If APTT > 40 seconds, additional protamine (25-50 mg i.v.).
Study NCT06315413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation using xenograft and composite plug
Description: Extraction of hopeless teeth will be followed by grafting the socket with xenograft and coverage with injected flowable composite plug which will then be stabilized using 5.0 polypropylene suture material with a figure of eight suture.
Study NCT06315413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket preservation using xenograft and intentionally exposed d-PTFE
Description: Extraction of hopeless teeth will be followed by grafting the socket with xenograft and coverage with d-PTFE membrane which will the be left exposed intentionally. This will be followed by securing the membrane using 5.0 polypropylene suture material with a figure of eight suture.
Study NCT04950322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701、CAPOX
Description: SHR-1701 with CAPOX (CAPOX:Oxaliplatin,Capecitabine)
Study NCT04950322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo、CAPOX
Description: Placebo with CAPOX (CAPOX:Oxaliplatin,Capecitabine)
Study NCT06562335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booster
Description: See description of arm. The Booster intervention has evolved from the PROfeel intervention. PROfeel is described in: https://doi.org/10.1186/s13063-022-06620-2
Study NCT06453005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SMART Hall Technique or procedure
Description: The SMART Hall technique, a minimally invasive approach in pediatric dentistry for managing caries in primary teeth, involves gentle cavity preparation using hand instruments and minimal local anesthesia. A glass ionomer cement is used for restoration, followed by crown adaptation and cementation. Postoperative care and follow-up assessments at 3 and 6 months are included.~The Stainless Steel Crown (SSC) technique for restoring extensively decayed primary molars involves tooth preparation, crown selection, adaptation, and cementation. Postoperative care and follow-up assessments at 3 and 6 months are also part of the procedure.
Study NCT06568354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: The yoga program was applied to all patients in this group, accompanied by a physiotherapist. Sessions included selected breathing, warm-up, and relaxation exercises.
Study NCT06568354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor control exercises
Description: Motor control exercises with three different progressive phases were applied to all patients in this group accompanied by a physiotherapist.
Study NCT04769908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Chemotherapy
Description: Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
Study NCT04769908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib, 8mg or 12mg, po, QD
Study NCT04769908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab, IV, 200mg, q3w
Study NCT04676386 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Primary Immune Response (PIR) test by Biodesix, Inc.
Description: Blood draw for biomarker assessment will be performed at these time-points: pretreatment, start of 3rd cycle and investigator assessed progression. The biomarker analysis will be performed retrospectively.
Study NCT04942080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CALR allele burden quantification
Description: * DNA extraction from blood sample for CALR mutation quantification (fragment analysis)~* at diagnosis and follow-up (inclusion period: 3 years)~* max 1 sample/year~* secondary outcome: mutational landscape by Next Generation Sequencing (NGS) analysis at diagnosis
Study NCT04947059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride combined with continuous saline irrigation
Description: Immediate single intravesical instillation with gemcitabine combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
Study NCT04947059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin Hydrochloride combined with continuous saline irrigation
Description: Immediate single intravesical instillation with epirubicin combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
Study NCT05885347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 360 videos
Description: Caregivers will receive 2h session of 360 videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in 360 videos instantly after the education and after 6 months.
Study NCT05885347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR
Description: Caregivers will receive 2h session of VR about caring and medication errors. Then Caregivers will be recorded performed the task worked inVR instantly after the education and after 6 months.
Study NCT05885347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AR
Description: Caregivers will receive 2h session of AR videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in AR videos instantly after the education and after 6 months.
Study NCT05728918 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antrodia cinnamomea mycelia
Description: Antrodia cinnamomea mycelia capsule, two capsules/day (600 mg/day) for 3 months
Study NCT05728918 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, two capsules/day (600 mg/day) for 3 months
Study NCT04778176 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: continuous oral delivery of levodopa/carbidopa
Description: The system consists of a reusable custom dental retainer, its case, and a pre-filled, single-use container which continuously releases levodopa/carbidopa into the back of the mouth.
Study NCT05885347 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Caregivers will follow the routine and then will be recorded performing their labour as a caregiver after 6 months.
Study NCT05241626 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AS-OCT
Description: Optical Coherence Tomography (OCT) creates detailed cross-sectional images of the anterior and posterior segments using low coherence interferometry. OCT is a noninvasive, real-time method for evaluating the tear meniscus, total corneal thickness (CT), and corneal epithelial thickness
Study NCT05335356 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stelara
Description: 45 mg , 90 mg at Week 0, 4, 16, 28 and 40; Before dosing at Week 16, patients in the Stelara group were randomly assigned in a 1:1 ratio to receive either Bmab 1200 or Stelara
Study NCT05335356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bmab1200
Description: 45 mg , 90 mg at Week 0, 4, 16, 28 and 40
Study NCT05290129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
Study NCT04133935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Obturator Urethropexy
Description: Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment.
Study NCT04133935 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Burch Urethropexy
Description: Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
Study NCT04939259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Music Program
Description: A mini behind-the-ear hearing aid that amplifies sounds and directs them into the ear. The music program within the hearing aid will provide amplification specifically tuned for listening to music.
Study NCT04939259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New Music Program
Description: A mini behind-the-ear hearing aid that amplifies sounds and directs them into the ear. The music program within the hearing aid will provide amplification specifically tuned for listening to music.
Study NCT04939259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Listening Program
Description: A mini receiver-in-the-ear hearing aid that amplifies sounds and directs them into the ear. The standard listening program within the hearing aid will provide amplification specifically tuned for listening to speech and daily general sounds in the environment.
Study NCT04939259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Listening Program
Description: A mini receiver-in-the-ear hearing aid that amplifies sounds and directs them into the ear. The standard listening program within the hearing aid will provide amplification specifically tuned for listening to speech and daily general sounds in the environment.
Study NCT04938037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine
Description: nerve block
Study NCT04938037 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine
Description: nerve block
Study NCT05319678 — intervention group
Intervention type: OTHER
Intervention: evaluation with Meludia music software
Description: Measurement instruments:~1. - MuMu Questionnaire~2. MuRQoL Questionnaire~3. Questionnaire for subjects aged 6-17 years~4. Music tool Meludia (www.meludia.com)~5. Acoustic analysis of the voice: the Praat programme~6. Audiological tests
Study NCT06087445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroLife EMG-FES Sleeve System
Description: Participants will complete a 12-week training protocol (3x/week, 1-2 hours/session) which includes an activity-based upper extremity training paradigm where participants will complete multiple repetitions attempting functional tasks in different categories (grip, grip with rotation, pinch, and pinch with rotation) while using the closed-loop EMG-FES system on one forearm/hand. Each category includes \~10 functional tasks (e.g., grip - open a jar; pinch with rotation - nuts and bolts) that progressively increase in difficulty. Each session will include massed practice of 3 functional tasks (20-minute blocks for each task) with rest breaks as needed to avoid fatigue. Sessions will include \~60 minutes of task practice, but they may last 1-2 hours to account for setup time and rest breaks.
Study NCT05810922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arbutus berry
Description: consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days
Study NCT06573957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patient in experimental arms will received intravenous dexmedetomidine at a dose of 0.5 µg/kg body weight 10 minutes before general anesthesia induction
Study NCT06573957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain
Description: Patient in experimental arms will receive intravenous lidocaine at 1.5 mg/kg body weight in a 5cc syringe 90 seconds before intubation
Study NCT06396728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GI BIOTICS 100B UFC
Description: Consumption of GI BIOTICS 100B UFC.
Study NCT06396728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Consumption
Description: Consumption of a placebo capsule.
Study NCT06384677 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: M-Tapa Block
Description: M-TAPA block was performed bilaterally with 20 mL of 0.2% bupivacaine under ultrasound guidance at the end of surgery
Study NCT05410912 — intervention group
Intervention type: PROCEDURE
Intervention: Great saphenous vein stripping and ambulatory phlebectomy
Description: All patients included in the study were treated with great saphenous vein stripping and ambulatory phlebectomy.
Study NCT05660109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPM502
Description: TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5
Study NCT05660109 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04725994 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IDX-1197+XELOX
Description: The dose levels will be escalated following a 3+3 dose escalation scheme.
Study NCT04725994 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IDX-1197+Irinotecan
Description: The dose levels will be escalated following a 3+3 dose escalation scheme.
Study NCT04960813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured games
Description: Camp Kidpower - Structured Games is an interactive, child-friendly camp and is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 15 different exercises will be taught. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Playgroup intervention.~Parents will be asked to attend an approximately one-hour group meeting, during which information is presented regarding child anxiety, effortful control and the rationale for this treatment. Parents are asked to continue to utilize the intervention at home every day if possible with the child and will receive texts or emails to track the games that are played at home.